Replies to post #3503 on Repros Therapeutics Inc (RPRX)

[corpstrat]

Not quite a response to my invitation
http://investorshub.advfn.com/boards/read_msg.asp?message_id=27104365

[io_io]

<The true efficacy of the drug is less than what was observed in phase-2....The reason is program-survival bias — in the aggregate, the efficacy seen in phase-2 trials of programs that are advanced to phase-3 is biased high relative to the true efficacy of the drugs in question.>

program-survival bias ? that's BS - like most drugs, Proellex is independent of other drugs - independent Data, independent Decision to go to Phase 3.


<an excessive number of dropouts and protocol violations occurs. The statistical power of a trial, reported to investors as 85% in the case of RPRX’s anemia trials, is highly sensitive to modeled assumptions about dropouts and protocol violations.>

also BS - the Power is NOT highly sensitive........nor is it complicated, they just model "a few"....pick a number on one hand.